KLK3 and prostate cancer: The observed refinement in prognostic predictions for patients with PSA levels below 4 ng/ml and those with a CR to initial treatment underscores the potential of the four key LncRNAs in predicting favorable outcomes, particularly in cases of early-stage and less malignant prostate cancer.